5-[3,3-Bis(2-chloroethyl)-1-triazeno]imidazole-4-carboxamide (NSC-82196) in the treatment of childhood malignancy.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy*; D009447:Neuroblastoma / Q000188:drug therapy; D009588:Nitrogen Mustard Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D012516:Osteosarcoma / Q000188:drug therapy; D012208:Rhabdomyosarcoma / Q000188:drug therapy; D012512:Sarcoma, Ewing / Q000188:drug therapy; D014226:Triazenes / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D007093:Imidazoles; D009588:Nitrogen Mustard Compounds; D014226:Triazenes